昌吉在线看男科(昌吉最正规的妇科医院) (今日更新中)

SAN FRANCISCO, June 13 (Xinhua) -- Google on Monday confirmed that it had signed an agreement to buy Admeld, an on-line advertising optimization firm, in a deal seen as the Internet search giant's latest move to bolster its on-line display ad business.Admeld, launched in 2007 and headquartered in New York City, has developed a service that can help on-line publishers manage their ad space more efficiently and profitably.Admeld now has more than 500 customers worldwide, among them are FOX News, IDG TechNetwork, Discovery and The Weather Channel, according to information posted on its website."By combining Admeld's services, expertise and technology with Google's offerings, we're investing in what we hope will be an improved era of flexible ad management tools for major publishers, " Neal Mohan, Google's vice president of display advertising, said in a blog post announcing the deal."We believe that this investment will be an important step to help on-line publishers, and will further improve and grow the display advertising industry as a whole," Mohan noted.On-line display ads usually appear in forms that consist of images and may be interactive. According to the Interactive Advertising Bureau, a U.S. trade association, display-related on- line ad revenue in the United States totaled nearly 10 billion U.S. dollars in 2010.Financial terms of the deal were not disclosed by the two companies. TechCrunch, a technology blog site, has reported that Google paid around 400 million dollars.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

ISLAMABAD, Sept.4 (Xinhua) -- Pakistan's eastern Punjab province is in the grip of a dengue epidemic with dozens of cases being reported daily at various hospitals across the province, said officials and hospital sources.A report issued by the provincial health department on Friday said that as many as 145 cases of dengue fever in Lahore, the provincial capital, and several other cities have been reported in Punjab over the past three days.The total dengue fever cases in the Punjab are 1,419 since the beginning of this year, out of which 1,358 Dengue patients had recovered and been discharged from hospitals, according to local media.Dengue, an acute febrile disease spread by the bite of the aedes aegypti has been endemic in Pakistan for the last few years. It spreads most often after the rainy season in July and August when pools of standing water serve as ideal mosquito breeding spots.Gravity of the dengue disease was felt at the central level and Prime Minister Yusuf Raza Gilani extended full support to the Punjab government in coping with the growing number of cases of dengue fever.The Prime Minister, who was in Lahore on Friday, directed his Principal Secretary to contact the Punjab government and assist them in taking necessary preventive measures against the Dengue fever. He also asked him to extend offer on behalf of the federal government for provision of any technical expertise to the Punjab government.Acting on reports that the virus was spreading rapidly and that measures to control it had been unsuccessful, Punjab Chief Minister Shahbaz Sharif has presided over series of meetings and ordered the immediate suspension of the Lahore district health officer for failing to control the epidemic.A task force comprising a government minister, health officials and doctors has been set up to review the situation and suggest measures to curb the virus.On the orders of the chief minister, giant advertisements on measures that can be taken to prevent dengue have appeared in the media.People have been advised not to allow water to stand in containers, to use mosquito repellents, spray homes and be particularly vigilant at dawn and twilight when the dengue- carrying mosquitoes bite.This increase in public vigilance and awareness may yet halt the spread of a disease that over the past few weeks has struck across the province, said specialists.Meanwhile, the Health Department spokesman also stressed awareness among the people for prevention, control and treatment of dengue virus. According to him, the symptoms of dengue fever include high fever, severe body pain, itching and red spots, bleeding from nose and teeth and severe pain in the eyes. He said precautions include proper covering of the pots having water, like buckets and drums, and using coils, mats and sprays for eliminating mosquitoes.He further said dengue mosquitoes usually attack early in the morning from 6 a.m. to 9 a.m. and from 4 p.m. to 10 p.m.in the evening. The patients should act upon the advice of qualified physicians only, he maintained.

SAN FRANCISCO, Sept. 22 (Xinhua) -- Facebook on Thursday introduced a new feature called Open Graph, enabling users to access and share a wide range of media and lifestyle content on the social network site.According to Facebook's chief executive officer (CEO) Mark Zuckerberg, Open Graph lets users share what they are doing in Facebook-connected apps as they are doing it.These social apps focus on media apps including books, news, music, TV, movies and games, as well as lifestyle apps such as exercise, food, fashion and travel."The last five years of social networking have been about getting people signed up, and getting people connected with their lives. The next five years are going to be defined by the apps and depth of engagement," the young CEO said in a keynote speech at Facebook's f8 developer conference.Take music for example, Facebook integrates with European music streaming service Spotify. If one's Spotify account is connected to Facebook, a message will show up in the Ticker stating the song one is listening to and in the Timeline, a new design of one's profile page. The friends of the user can listen to the same song at the same time by hovering mouse over the song in Timeline or Ticker.Spotify founder and CEO Daniel Ek and movie streaming service Netflix CEO Reed Hastings also took stage as guest speakers to introduce their partnership with Facebook.Zuckerberg also introduced social news reading applications from major news organizations such as The Washington Post and Yahoo News, which allow users to access the content directly on Facebook.Earlier at the f8 conference, Timeline was unveiled as a new feature. It is a new profile design allowing users to scroll vertically through the big moments of one's life in a single page.Zuckerberg assured users that they have complete control over their Timeline, saying they can decide what content will appear and who can see it. The new feature will be available in a few weeks.Since Google launched its own social network "Google+" in June, Facebook has been in a combat mode, striving to roll out new products and features to beat the search giant. In his keynote speech on Thursday, Zuckerberg said half a billion people now use Facebook every day.Two days before the f8 conference, Google announced to open its social network to the public, noting it has introduced 100 new features in the three-month trial.

BEIJING, Aug. 2 (Xinhuanet) -- The first close-up pictures of the asteroid Vesta, a protoplanet that dates back to the early days of the solar system, were revealed Monday by NASA scientists.The images were taken by the U.S. space agency's Dawn robotic probe, which is two weeks into a planned year-long survey of the second largest object in the main asteroid belt, located between Mars and Jupiter.About twice the size of California, Vesta is second in size only to Ceres, Dawn's next target and, along with Pluto, one of just five known dwarf planets. NASA is spending 466 million dollars to explore Vesta and Ceres during the course of a 10-year mission.Images from Dawn show Vesta a surprisingly diverse terrain and several unexplained geologic features. Chaotic terrain near the south pole is dominated by a towering central peak and huge ripple-like grooves stretching around its equatorial belt. Bright spots, dark pits and craters are filled with unexplained streaks of black and white debris. Terrain north of the grooves is much more heavily cratered.Scientists believe Vesta grew from a clump of gas and dust left over after the sun's birth some 4.65 billion years ago, a supernova explosion, which added radioactive materials to the growing body.Dawn will spend about a year circling Vesta, tweaking its orbit and altitude using an innovative technology called ion propulsion system, chief engineer Marc Rayman with NASA's Jet Propulsion Laboratory in California said.The ion propulsion system will enable Dawn to leave Vesta's orbit after a year of study and head off to Ceres, which is the largest object in the asteroid belt.

来源：资阳报